Your trusted source for investing success

Tag: biopharmaceutical

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the Human Genetic Resources Administration of China (HGRAC), has approved the Company’s application to initiate a Phase 2 safety and efficacy study of its lead product candidate VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the completion of the first site initiation visit at the Dent Neurological Institute (“Dent”) for its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (“STAR-3”).  Site initiation visits are generally the final step before patient enrollment.

The

Canadian Marijuana Stocks

Canadian Marijuana Stocks

The Canadian marijuana sector is one of the hottest growing sectors. Here’s a look at Canadian cannabis companies for investors to consider.

5 Top Biotech Stocks on the TSX Year-to-date

5 Top Biotech Stocks on the TSX Year-to-date

The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.

DelMar Pharmaceuticals Joins National Brain Tumor Society’s Research Roundtable

DelMar Pharmaceuticals Joins National Brain Tumor Society’s Research Roundtable

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on developing new cancer therapies, announced today that Jeffrey Bacha, Chief Executive Officer and Dennis Brown, Chief Scientific Officer have accepted invitations to join the National Brain Tumor Society’s (NBTS) Research Roundtable.

The inaugural meeting entitled, “Streamlining Clinical Trials to Accelerate Brain

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced it has received Institutional Review Board (IRB) approval to conduct its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3).

“IRB approval is an essential step in initiating patient enrollment in our

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network